<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04638309</url>
  </required_header>
  <id_info>
    <org_study_id>A20-11202</org_study_id>
    <nct_id>NCT04638309</nct_id>
  </id_info>
  <brief_title>APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)</brief_title>
  <official_title>Phase 1 Study to Evaluate Safety and Efficacy of APR-548 in Combination With Azacitidine for the Treatment of TP53-Mutant Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aprea Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aprea Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 study evaluating the safety and efficacy of APR-548 in combination with Azacitidine&#xD;
      for the treatment of TP53-Mutant Myelodysplastic Syndromes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label first-in-human (FIH) phase 1 clinical trial assessing the safety, pharmacokinetics&#xD;
      (PK), and clinical activity of orally (p.o.) administered APR-548 alone and in combination&#xD;
      with azacitidine for the treatment of TP53-mutant myelodysplastic syndromes (MDS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the safety and tolerability of APR-548 as monotherapy and in combination with azacitidine.</measure>
    <time_frame>Through study completion, approximately 1 year</time_frame>
    <description>Occurence of dose limiting toxicities (DLTs) and frequency of treatment emergent and serious adverse events.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>MDS</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APR-548 + Azacitidine</intervention_name>
    <description>APR-548 monotherapy period followed by APR-548 in combination with Azacitidine</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated, written informed consent prior to any study specific&#xD;
             procedures.&#xD;
&#xD;
          2. Documented diagnosis of TP53-mutant MDS, according to WHO criteria that is&#xD;
             relapsed/refractory or previously untreated MDS.&#xD;
&#xD;
          3. Adequate organ function as defined by the following laboratory values:&#xD;
&#xD;
               1. Creatinine clearance ≥60 mL/min (by Cockcroft-Gault method, Appendix I),&#xD;
&#xD;
               2. Total serum bilirubin ≤1.5 × upper limit of normal (ULN) unless due to Gilbert's&#xD;
                  syndrome or MDS organ involvement,&#xD;
&#xD;
               3. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN,&#xD;
                  unless due to MDS organ involvement.&#xD;
&#xD;
          4. Age ≥18 years at the time of signing the informed consent form.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 (Appendix&#xD;
             II).&#xD;
&#xD;
          6. Projected life expectancy of ≥12 weeks.&#xD;
&#xD;
          7. Clear ocular media and adequate pupil dilation to permit fundus examination and&#xD;
             retinal imaging.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cardiac abnormalities, which includes, but not limited to:&#xD;
&#xD;
               1. Myocardial infarction within six months prior to enrollment&#xD;
&#xD;
               2. New York Heart Association Class III or IV heart failure or known LVEF &lt;40%&#xD;
&#xD;
          2. Concomitant malignancies or previous malignancies with less than a 1 year disease-free&#xD;
             interval at the time of signing informed consent.&#xD;
&#xD;
          3. Use of cytotoxic chemotherapeutic agents, or experimental agents for the treatment of&#xD;
             MDS within 14 days or 5 half-lives of the product (whichever is shorter) of the first&#xD;
             day of study drug treatment.&#xD;
&#xD;
          4. Prior exposure to eprenetapopt (APR-246).&#xD;
&#xD;
          5. A female subject who is pregnant or breast-feeding.&#xD;
&#xD;
          6. Known history of human immunodeficiency virus (HIV), active hepatitis B or active&#xD;
             hepatitis C infection.&#xD;
&#xD;
          7. Malabsorption syndrome or other condition likely to affect gastrointestinal absorption&#xD;
             of APR-548.&#xD;
&#xD;
          8. Known history or current evidence of ocular disease in either eye&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joachim Gullbo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Theradex Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eyal Attar, MD</last_name>
    <phone>1 617 804 6947</phone>
    <email>info@aprea.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Sallman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Brunner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institue</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Winer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Garcia-Manero, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

